These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 19675541)

  • 1. Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
    Zamboni WC; Strychor S; Maruca L; Ramalingam S; Zamboni BA; Wu H; Friedland DM; Edwards RP; Stoller RG; Belani CP; Ramanathan RK
    Clin Pharmacol Ther; 2009 Nov; 86(5):519-26. PubMed ID: 19675541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.
    Zamboni WC; Strychor S; Joseph E; Walsh DR; Zamboni BA; Parise RA; Tonda ME; Yu NY; Engbers C; Eiseman JL
    Clin Cancer Res; 2007 Dec; 13(23):7217-23. PubMed ID: 18056203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
    Wu H; Ramanathan RK; Zamboni BA; Strychor S; Ramalingam S; Edwards RP; Friedland DM; Stoller RG; Belani CP; Maruca LJ; Bang YJ; Zamboni WC
    J Clin Pharmacol; 2012 Feb; 52(2):180-94. PubMed ID: 21233302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies.
    Zamboni WC; Ramalingam S; Friedland DM; Edwards RP; Stoller RG; Strychor S; Maruca L; Zamboni BA; Belani CP; Ramanathan RK
    Clin Cancer Res; 2009 Feb; 15(4):1466-72. PubMed ID: 19190127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STEALTH liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models.
    Yu NY; Conway C; Pena RL; Chen JY
    Anticancer Res; 2007; 27(4B):2541-5. PubMed ID: 17695551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors.
    Zamboni WC; Maruca LJ; Strychor S; Zamboni BA; Ramalingam S; Edwards RP; Kim J; Bang Y; Lee H; Friedland DM; Stoller RG; Belani CP; Ramanathan RK
    J Liposome Res; 2011 Jun; 21(2):158-65. PubMed ID: 20626314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients.
    Wu H; Ramanathan RK; Zamboni BA; Strychor S; Ramalingam S; Edwards RP; Friedland DM; Stoller RG; Belani CP; Maruca LJ; Bang YJ; Zamboni WC
    Int J Nanomedicine; 2012; 7():5555-64. PubMed ID: 23112576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients.
    La-Beck NM; Zamboni BA; Gabizon A; Schmeeda H; Amantea M; Gehrig PA; Zamboni WC
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):43-50. PubMed ID: 21590446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models.
    Zamboni WC; Eiseman JL; Strychor S; Rice PM; Joseph E; Zamboni BA; Donnelly MK; Shurer J; Parise RA; Tonda ME; Yu NY; Basse PH
    J Liposome Res; 2011 Mar; 21(1):70-80. PubMed ID: 20528623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allometric scaling of pegylated liposomal anticancer drugs.
    Caron WP; Clewell H; Dedrick R; Ramanathan RK; Davis WL; Yu N; Tonda M; Schellens JH; Beijnen JH; Zamboni WC
    J Pharmacokinet Pharmacodyn; 2011 Oct; 38(5):653-69. PubMed ID: 21863380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.
    Wu H; Infante JR; Keedy VL; Jones SF; Chan E; Bendell JC; Lee W; Kirschbrown WP; Zamboni BA; Ikeda S; Kodaira H; Rothenberg ML; Burris HA; Zamboni WC
    Int J Nanomedicine; 2015; 10():1201-9. PubMed ID: 25709442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin.
    Gabizon A; Isacson R; Rosengarten O; Tzemach D; Shmeeda H; Sapir R
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):695-702. PubMed ID: 17549475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
    Dadashzadeh S; Vali AM; Rezaie M
    Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients.
    Bedikian AY; Vardeleon A; Smith T; Campbell S; Namdari R
    J Clin Pharmacol; 2006 Jul; 46(7):727-37. PubMed ID: 16809798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
    Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
    Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors.
    Wu H; Infante JR; Keedy VL; Jones SF; Chan E; Bendell JC; Lee W; Zamboni BA; Ikeda S; Kodaira H; Rothenberg ML; Burris HA; Zamboni WC
    Eur J Clin Pharmacol; 2013 Dec; 69(12):2073-81. PubMed ID: 23989300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
    Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
    Cancer Chemother Pharmacol; 2009 May; 63(6):1049-63. PubMed ID: 18791718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.
    Vergote I; Finkler N; del Campo J; Lohr A; Hunter J; Matei D; Kavanagh J; Vermorken JB; Meng L; Jones M; Brown G; Kaye S;
    Eur J Cancer; 2009 Sep; 45(13):2324-32. PubMed ID: 19515553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents.
    Schell RF; Sidone BJ; Caron WP; Walsh MD; White TF; Zamboni BA; Ramanathan RK; Zamboni WC
    Nanomedicine; 2014 Jan; 10(1):109-17. PubMed ID: 23891988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.